Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ascentage Pharma Group International ( (HK:6855) ) has issued an update.
Ascentage Pharma announced the selection of five preclinical studies from its innovative pipeline for presentation at the 2025 American Association of Cancer Research Annual Meeting. The studies highlight promising results from drug candidates such as olverembatinib, lisaftoclax, APG-2449, APG-5918, and AS03157, showcasing the company’s advancements in cancer therapeutics. This announcement underscores Ascentage Pharma’s commitment to advancing cancer treatment and may enhance its position in the oncology sector, potentially benefiting stakeholders and patients alike.
More about Ascentage Pharma Group International
Ascentage Pharma Group International is a biopharmaceutical company incorporated in the Cayman Islands. The company focuses on developing innovative therapies for cancer treatment, with a pipeline that includes novel drug candidates targeting key proteins involved in cancer cell survival and proliferation.
YTD Price Performance: -18.15%
Average Trading Volume: 3,476,113
Technical Sentiment Signal: Sell
Current Market Cap: HK$12.74B
Learn more about 6855 stock on TipRanks’ Stock Analysis page.